Modern trends in treatment of diabetes mellitus in patients with hepatopathy

Czech version

Authors: Dana Prídavková; Veronika Sváková; Peter Galajda; Marián Mokáň
Authors‘ workplace: I. interná klinika Jesseniovej LF UK a UNM, Martin
Published in: Forum Diab 2019; 8(2): 133-137
Category: Review Article

Overview

The range of liver diseases that may occur during the duration of diabetes mellitus goes from asymptomatic hepatic enzyme abnormalities, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), hepatic cirrhosis to hepatocellular carcinoma (HCC), and also includes viral and autoimmune hepatitis, venostatic, or rare metabolic diseases. In recent years, there was new evidence of a positive impact of new antidiabetic treatment on the development of some liver diseases.

Keywords:

antidiabetic treatment – liver damage

Sources

Kawaguchi T, Taniguchi E, Itou M et al. Insulin resistance and chronic liver disease. World J Hepatol 2011; 3(5): 99–107. Dostupné z DOI: <http://dx.doi.org/10.4254/wjh.v3.i5.99>.
Blendea MC, Thompson MJ, Malkani S. Diabetes and chronic liver disease: Etiology and pitfalls in monitoring. Clin Diabetes 2010; 28(4): 139–144. Dostupné z DOI: <http://dx.doi.org/10.2337/diaclin.28.4.139>.
Gangopadhyay KK, Singh P. Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. Indian J Endocr Metab 2017; 21(2): 341–354. Dostupné z DOI: <http://dx.doi.org/10.4103/ijem.IJEM_512_16>.
Nascimbeni F, Aron-Wisenewsky J, Pais R et al. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver diasease. BMJ Open Gastroenterol 2016; 3(1): e000075. Dostupné z DOI: <http://10.1136/bmjgast-2015–000075>.
Hamed AE, Abas B, Shaltout I et al. Managing Diabetes and Liver Disease Association, Guidelines (Consensus) Development. J Endocrinol Diabetes Obes 2015; 3(3): 1073.
[European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO)]. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016; 59(6): 1121–1140. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–016–3902-y>.
Iogna Prat L, Tsochatzis EA. The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). Hormones 2048; 17(2): 219–229. Dostupné z DOI: <http://dx.doi.org/10.1007/s42000–018–0021–9>.
Sumida Y, Seko Y, Yoneda M. Japan study Group of NAFLD (JSG-NAFLD). Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res 2017; 47(4): 266–280. Dostupné z DOI: <http://dx.doi.org/10.1111/hepr.12856>.
Armstrong MJ, Adams LA, Canbay A et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014; 59(3): 1174–1197. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.26717>.
Davies MJ, D’Alessio DA, Fradkin J et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61(12): 2461–2498. Dostupné z DOI: <http://dx.doi.org/doi.org/10.1007/s00125–018–4729–5>.
Tacelli M, Celsa C, Magro B et al. Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? Pharmaceuticals (Basel) 2018; 11(4): pii: E121. Dostupné z DOI: <http://dx.doi.org/10.3390/ph11040121>.
Said A, Akhter A. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis. Ann Hepatol 2017; 16(4): 538–547. Dostupné z DOI: <http://dx.doi.org/10.5604/01.3001.0010.0284>.
Haukeland JW, Konopski Z, Eggesbø HB et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009; 44: 853–860. Dostupné z DOI: <http://dx.doi.org/10.1080/00365520902845268>.
Shields WW, Thompson KE, Grice GA et al. The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol 2009; 2(3): 157–163. Dostupné z DOI: <http://dx.doi.org/10.1177/1756283X09105462>.
Uygun A, Kadayifci A, Isik AT et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19(5): 537–544.
Bugianesi E, Gentilcore E, Manini R et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100(5): 1082–1090. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1572–0241.2005.41583.x>.
Iranshahy M, Rezaee R, Karimi G. Hepatoprotective activity of metformin: A new mission for an old drug? Eur J Pharmacol 2019; 850: 1–7. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejphar.2019.02.004>.
Zhang X, Harmsen WS, Mettler TA et al. Continuation of Metformin Use After a Diagnosis of Cirrhosis Significantly Improves Survival of Patients With Diabetes. Hepatology 2014; 60(6): 2008–2016. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.27199>.
Cui J, Philo L, Nguyen P et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. J. Hepatol 2016; 65(2): 369–376. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jhep.2016.04.021>.
Joy TR, McKenzie CA, Tirona RG et al. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J Gastroenterol 2017; 2(1)3: 141–150. Dostupné z DOI: <http://dx.doi.org/10.3748/wjg.v23.i1.141>.
Yilmaz Y, Yonal O, Deyneli O et al. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg 2012; 75(2): 240–244.
Hussain M, Majeed Babar MZ, Hussain MS et al. Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with nonalcoholic fatty liver disease. Pak J Med Sci 2016; 32(6): 1396–1401. Dostupné z DOI: <http://dx.doi.org/10.12669/pjms.326.11133>.
Sayari S, Neishaboori H, Jameshorani M. Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease. Clin Mol Hepat 2018; 24(3): 331–338. Dostupné z DOI: <http://dx.doi.org/10.3350/cmh.2018.0006>.
Armstrong MJ, Gaunt P, Aithal GP et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, doubl-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387(10019): 679–690. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(15)00803-X>.
Trulicity: EPAR - Product Information. European Medicines Agency. Dostupné z WWW: <https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity#product-information-section>
Cusi K, Sattar N, Garcia- Pérez LE et al. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. Diabet Med 2018; 35(10): 1434–1439. Dostupné z DOI: <http://dx.doi.org/10.1111/dme.13697>.
Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. N Engl J Med 2010; 362(18): 1675–1685. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0907929>.
Kalra S. Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Ther 2014; 5(2): 355–366. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–014–0089–4>.
Jojima T, Tomotsune T, Iijima T et al. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linaglitpin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr 2016; 8: 45. Dostupné z DOI: <http://dx.doi.org/10.1186/s13098–016–0169-x>.
Kuchay MS, Krishan S, Mishra SK et al. Effect of Empagliflozin on Liver fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial). Diabetes Care 2018; 41(8): 1801–1808. Dostupné z DOI: <http://dx.doi.org/10.2337/dc18–0165>.
Chalasani N, Younossi Z, Lavine JE et al. The Diagnosis and Management of Noncalcoholic Fatty Liver Disease. Practice Guidance From American Association for the Study of Liver Diseases. Hepatology 2018; 67(1):328–357. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.29367>.